Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of REGN15505 Alone or in Combination for mCRPC and ccRCC
NCT07594106Phase 2Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jul 2026
- Primary completion
- Oct 2030
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of REGN15505 in metastatic castration-resistant prostate cancer (mCRPC), clear cell renal cell carcinoma (ccRCC), sponsored by Regeneron Pharmaceuticals. Started Jul 2026; status: recruiting.
02
Drugs
REGN15505
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07594106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07594106.